Catalent Pharma Solutions Appoints New Chief Financial Officer

Catalent Pharma Solutions, Inc. announced today the appointment of
Matthew M. Walsh as Senior Vice President, Finance and Chief Financial
Officer, effective April 7, 2008. David A. Eatwell, the incumbent in
this role, will be leaving Catalent effective April 4, 2008 to pursue
other opportunities.

Matthew Walsh, 41, brings to Catalent extensive public company
financial leadership experience, most recently as President and Chief
Financial Officer of Escala Group, Inc., a global collectibles network
and precious metals trader. From 1996 through 2006, Mr. Walsh held
positions of increasing responsibility in corporate development,
accounting and finance at diversified industrial manufacturer GenTek,
Inc., culminating in his appointment as Vice President and Chief
Financial Officer. Prior to GenTek, he served in corporate development
and other roles in banking and the chemicals industry. Mr. Walsh
received a Bachelor of Science degree in chemical engineering and a
Master of Business Administration degree from Cornell University, and
is a CFA(R) charterholder.

John Lowry, President and Chief Executive Officer of Catalent,
said, "I am pleased to welcome Matt as the newest member of our
Catalent executive team. His unique combination of experience across
operational, treasury and financial disciplines, combined with his
public company experience, will enable him to contribute significantly
to our success." Mr. Lowry added, "I would also like to recognize
David Eatwell´s important contributions to Catalent over his career,
and wish David success in his future endeavors."

About Catalent

Headquartered in Somerset, New Jersey, Catalent Pharma Solutions
is the leading provider of advanced technologies, and development,
manufacturing and packaging services for pharmaceutical, biotechnology
and consumer healthcare companies in nearly 100 countries. Catalent
applies its local market expertise and technical creativity to advance
treatments, change markets and enhance patient outcomes. Catalent
employs approximately 10,000 at more than 30 facilities worldwide and
generates more than $1.7 billion of annual revenue. For more
information, visit www.catalent.com.